From China Leadership to Global Premier:

Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization

SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2025 annual results and long-term strategic blueprint.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "2025 marks the most successful year in Innovent's history. We achieved historic breakthroughs across three areas: business scale, financial strength, and global innovation. We successfully upgraded our strategy from an oncology-focused leader to a 'dual-engine growth model' driven by oncology and general biomedicine portfolio.

Encouragingly, we delivered our first full year of net profit, marking a formal entry into an era of sustainable profitability. Our robust cash reserves and positive operating cash flow will provide strong support for strategic growth. On the innovation front, three global high-potential assets advanced into or near global registrational clinical development, targeting a combined addressable market value of over US$60 billion. Meanwhile, we accelerated the global value realization of our pipeline through multiple landmark strategic collaborations, laying a solid foundation for global expansion. Total deal value reached over US$22 billion in the past year, accounting for more than 10% of China's innovative pharmaceutical sector outbound licensing value in 2025^[1].

These achievements not only validate the foresight of our strategy but also highlight our uniqueness of strong growth and high certainty within China's biopharma industry. Guided by our Vision 2030 to become a global premier biopharmaceutical company, we will continue to drive progress across four core pillars: revenue, profitability, innovative pipeline and organizational capabilities, creating sustainable value for patients, shareholders and society."

Revenue Set New Height, Achieved Full-Year Profitability with Strong Cash Position

Total revenue reached RMB 13.0 billion, representing a year-on-year increase of 38.4%. Product revenue amounted to RMB 11.9 billion, up 44.6% year-on-year. From the commercial launch of its first product in 2019 to 18 approved products and surpassing RMB 10 billion revenue milestone, Innovent accomplished this in only 7 years, setting a new growth benchmark for China's innovative biopharmaceutical industry.

The Company achieved its first full year of net profit. IFRS net profit reached RMB 814 million, and Non-IFRS net profit rose to RMB 1.72 billion, marking a structural inflection in profitability and entry into a sustainable earnings era.

Operating efficiency continued to improve. Gross margin improved 2.3 percentage points to 87.2%. Selling and administrative expense ratio declined 2.9 percentage points to 48.0%. EBITDA surged to RMB 1.99 billion (2024: RMB 412 million). As of December 31, 2025, cash reserves totaled RMB 24.3 billion (~US$3.5 billion). Additionally, the Company also generated positive operating cash flow, providing strong financial support for long-term development. ^[2]

Dual-Engine Strategy Fully Implemented, Commercial Foundation Strengthened

China Leading Oncology Brand with Synergistic Value of Innovative Portfolio

Innovent has established a leading oncology brand in China. Cornerstone products including TYVYT^® (sintilimab injection), BYVASDA^® (bevacizumab injection) and HALPRYZA^® (rituximab injection) have benefited millions of Chinese cancer patients.

In addition, five small-molecule targeted oncology drugs—Limertinib (EGFR TKI), DOVBLERON^® (Taletrectinib, ROS1i), Dupert^® (fulzerasib, KRAS G12Ci), JAYPIRCA^® (Pirtobrutinib, BTKi), and Retsevmo^® (selpercatinib, RETi) — were successfully included in the 2025 National Reimbursement Drug List (NRDL), further strengthening the competitiveness and commercial performance of Innovent's oncology portfolio.

General Biomedicine Franchise Emerged as a New Growth Engine

Benefiting from forward-looking strategic layout, Innovent's general biomedicine portfolio delivered strong momentum in 2025.

SYCUME^® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO^® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE^® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025.

Within a single year, the general biomedicine portfolio has become a second core engine driving high-speed growth. Today, Innovent possesses one of the highest-quality commercial portfolio and pipeline in the industry, supported by a fully established commercial network, reinforcing its solid commercial foundation.

Year of Globalization: Pipeline Value Unlocked, Growth Potential Expanded

2025 marked a breakthrough year for the Company's globalization strategy, unlocking substantial long-term growth potential. Innovent successfully advanced three core assets into or near global Phase 3 clinical trials. According to its partner estimates, these late-stage assets target a combined total addressable market (TAM) of over US$60 billion, including:

IBI363 (PD-1/IL-2^α-bias): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications

• In collaboration with Takeda, IBI363 is being advanced globally. The first global MRCT Phase 3 in IO-resistant squamous NSCLC has been initiated. PoC in IO-resistant non-squamous NSCLC is completed, with a new global Phase 3 planned subject to the PoC results and regulatory communications. A Phase 3 trial in 3L colorectal cancer (CRC) in China is planned for 2026. A Phase 2 trial in IO-naïve mucosal/acral melanoma is underway in China. PoC studies in 1L NSCLC and 1L CRC are ongoing.

IBI343 (CLDN18.2 ADC): Cornerstone for gastrointestinal cancers, potential TAM over US$8 billion

• Interim analysis from the China-Japan Phase 3 clinical trial in 3L gastric cancer is expected in 2026. Phase 3 in 3L pancreatic cancer in China was initiated in 2025. PoC studies in 1L gastric and 1L pancreatic cancer are ongoing.

IBI324 (VEGF/ANG2): Potential best-in-class retinaltherapy, potential TAM US$15 billion

• Our partner Ollin Biosciences reported positive top-line results from the Phase 1b JADE head-to-head study against faricimab in wAMD and DME patients in the US. Innovent is working closely with Ollin to engage global regulators in 2026 and advance IBI324 into global Phase 3 trials.

Diversified Partnerships to Accelerate Global Innovation

Total deal value from Innovent's global collaborations reached over US$22 billion in 2025, representing over 10% of China's innovative pharma outbound licensing value. These partnerships not only accelerate global pipeline development but also help build core capabilities for Innovent to become a truly world-class biopharma.

• With Takeda: Landmark "IO + ADC" collaboration under a co-development and co-commercialization ("Co-Co") model for IBI363 to build its global R&D and commercialization capabilities.
• With Eli Lilly: Seventh partnership with an end-to-end innovation model to jointly develop novel oncology and immunology molecules, enhancing full lifecycle R&D frameworks and decision-making from a multinational perspective.
• With Roche: Leveraging global oncology resources to advance IBI3009 (DLL3 ADC) worldwide.
• With Ollin: Utilizing global ophthalmology expertise to accelerate IBI324's clinical development and market positioning.

High-Quality Manufacturing Standards

• Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Site 1 houses 60,000 liters of antibody capacity and ADC commercial lines; Site 2 has 80,000 liters of antibody capacity, supporting global supply and CDMO services.

Sustainable Development and ESG Commitment

• 8,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou.
• Over 3,000 new cancer patients initiate Innovent therapies daily; more than 6 million patients have benefited to date.
• Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry.
• First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status).
• Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management.
• Published patient education materials on thyroid eye disease and weight management to enhance public health awareness.
• Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 3.6 billion.
• Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise".
• Created over 2,200 jobs for new graduates.
• Cumulative taxes and contributions exceeding RMB 6 billion.

Vision 2030: From China Leader to Global Premier Biopharma

Entering 2026, Innovent celebrates its 15th anniversary. Building on its strong foundation, the Company reaffirms Vision 2030: to evolve into a global premier biopharmaceutical company.

• Revenue: Target RMB 20 billion by 2027 with continued expansion thereafter. International revenue will become a new growth driver in the future.
• Profitability: Maintain high-quality growth while steadily improving profit margins benchmarking industry-leading levels.
• Pipeline: Focus on advancing high-value assets including IBI363, IBI343 and IBI324. Push next-generation oncology and general biomedicine molecules into global early-stage and PoC studies. Target at least 5 molecules in global MRCT Phase 3 by 2030.
• Organization: Established a US R&D and operating team of nearly 100 people. Through deep partnerships with Takeda, Lilly, Ollin, Roche and others, Innovent is rapidly building global R&D, regulatory and commercial capabilities. These growing global competencies will further support independent development, enabling Innovent to leap forward into a fully independent, world-class biopharmaceutical enterprise.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

• Innovent does not recommend the use of any unapproved drug (s)/indication (s).
• Ramucirumab (Cyramza)，Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

香港2026年3月26日 /美通社/ -- 中國海洋石油有限公司（「公司」或「中國海油」，香港聯交所股票代碼：00883（港幣櫃台）及80883（人民幣櫃台），上海證券交易所股票代碼：600938）今天公佈了截至2025年12月31日的2025年年度業績。

• 淨產量約213萬桶油當量/日
• 歸母淨利潤達1,221億元
• 派息率45%，全年股息1.28港元/股（含稅）

業績回顧

中國海油堅持穩健的產量增長和嚴格的成本管控，不斷築牢成本競爭優勢和盈利韌性。五年來，公司累計獲得66個新發現，淨產量年均複合增長率約8%。2025年，公司淨產量約213萬桶油當量/日，歸母淨利潤達人民幣1,221億元。

公司堅持價值勘探主線，油氣儲量再創新高，首次榮獲伍德麥肯茲「年度最佳國家石油公司勘探企業」獎。2025年，共獲得6個油氣新發現，成功評價28個含油氣構造。淨證實儲量達77.7億桶油當量，同比增長6.9%。在中國境內，獲得新發現龍口25-1，成功評價秦皇島29-6，充分揭示了渤海淺層岩性良好的勘探前景。在海外，圭亞那Stabroek區塊成功評價Lukanani和Ranger兩個油田，不斷夯實該區塊資源基礎。此外，在伊拉克、哈薩克斯坦和印度尼西亞獲取4個勘探新項目，進一步豐富了海外油氣資產組合。

公司油氣產量再創新高，在產油田開發效益顯著。2025年順利投產多個新項目，在產油田儲量動用率和採收率持續提升，全年實現油氣淨產量777.3百萬桶油當量，同比增長7%。其中，原油增長5.8%；天然氣大幅增長11.6%，為公司保持盈利韌性提供了有益助力。公司深化穩油控水，規模化應用智能注採技術，助力中國海上油田自然遞減率降至9.5%，維持較好水平。在海外，南美洲、北美洲等多個項目產量保持增長，已成為公司產量增長的重要來源。

公司堅持科技創新，有效驅動內生增長。在勘探開發方面，公司規模化應用先進地球物理技術，大幅提升深層地震資料質量，助力發現惠州19-6億噸級深層油田。中國海上平均鑽井日效率實現五年來最好水平，優智鑽完井示範項目提速26%。此外，深水水下採油樹及控制系統取得積極進展。在數智化轉型方面，公司深入實施「人工智能+」行動，智能應用油氣勘探開發、安全生產及研究等關鍵場景提效超30%，海上平台無人化率穩步提升。「深海一號」智慧氣田入選中國首批領航級智能工廠培育名單。

公司堅持油氣清潔生產，推動新能源新產業發展。公司深入踐行綠色低碳發展戰略，持續擴大伴生氣回收利用規模，構建全方位綠色發展體系。2025年公司通過岸電工程等持續提高綠電用量，全年使用綠電10.8億千瓦時，減碳68萬噸。海上風電規模化資源獲取和示範項目建設邁出堅實步伐，CCS/CCUS等負碳業務發展穩健。「海油觀瀾號」穩定運行，海南CZ7風電項目和全球首座16兆瓦級張力腿型浮式風電平台項目建設有序推進。中國首個海上 CCUS 示範項目在恩平15-1油田順利投用，大亞灣區CCS/CCUS集群示範項目完成技術可行性研究。

公司克服國際油價震盪下行帶來的不利影響，通過穩定的產量增長和務實有效的提質降本增效舉措，保持盈利韌性。2025年油氣銷售收入達人民幣3,357億元，歸母淨利潤達人民幣1,221億元。全年桶油主要成本為27.9美元/桶油當量，同比下降2.2%。公司積極與股東共享發展成果，董事會建議2025年派息率45%，折合全年股息1.28港元/股（含稅），其中，末期股息0.55港元/股（含稅）。

中國海油積極履行企業社會責任，為社會發展貢獻力量。2025年，公司在助力鄉村振興、推動教育公平、保護自然生態、促進民生福祉等方面持續發力，積極開展公益慈善活動。公司榮獲「最受尊崇企業」、「最佳雇主」等多項榮譽。

2026年主要經營目標

2026年，中國海油將專注油氣主業，持續追求有效益的產量，全年產量目標為780-800百萬桶油當量。在支持產量穩步增長的同時，2026年資本支出預算保持穩定，為人民幣1,120-1,220億元。

公司董事長張傳江先生表示：「展望未來，我們將以油氣增儲上產築牢發展底氣，以價值創造賦能發展動力，以創新驅動引領產業升級，以國際化發展構建競爭優勢，以綠色低碳積蓄發展潛力，奮力打造具有鮮明海洋特色的世界一流能源資源集團，與利益相關方攜手共赴發展新征程。」

— 完 —

編者注：

如需瞭解中國海洋石油有限公司更多信息，請登陸公司網站https://www.cnoocltd.com

*** *** *** ***

本新聞稿包含公司的前瞻性資料，包括關於本公司和其附屬公司業務相當可能有的未來發展的聲明，例如預期未來事件、業務展望或財務結果。「預期」、「預計」、 「繼續」、 「估計」、 「目標」、 「持續」、 「可能」、 「將會」、 「預測」、 「應當」、 「相信」、 「計劃」、 「旨在」等詞匯以及相似表達意在判定此類前瞻性聲明。這些聲明以本公司在此日期根據其經驗以及對歷史發展趨勢，目前情況以及預期未來發展的理解，以及本公司目前相信的其它合理因素所做出的假設和分析為基礎。然而，實際結果和發展是否能夠達到本公司的目前預期和預測存在不確定性，取決於一些可能導致實際業績、表現和財務狀況與本公司的預期產生重大差異的不確定因素，這些因素包括但不限於宏觀政治及經濟因素、原油和天然氣價格波動有關的因素、石油和天然氣行業高競爭性的本質、氣候變化及環保政策因素、公司價格前瞻性判斷、並購剝離活動、HSSE及保險安排、以及與反腐敗、反舞弊、反洗錢及公司治理相關法規變化。

因此，本新聞稿中所做的所有前瞻性聲明均受這些謹慎性聲明的限制。本公司不能保證預期的業績或發展將會實現，或者即便在很大程度上得以實現，本公司也不能保證其將會對本公司、其業務或經營產生預期的效果。

*** *** *** ***

如有進一步查詢，請聯絡：

劉  翠
媒體/公共關係
中國海洋石油有限公司
電話：+86-10-8452-6641
傳真：+86-10-8452-1441
電郵：[email protected]

程  遙
九富（香港）財訊公關集團有限公司
電話: +852 5540 0725
傳真: +852 2111 1103
電郵：[email protected]

Reflection AI, an AI startup backed by Nvidia (NVDA.US), is in talks to raise USD2.5 billion at a valuation of USD25 billion, The Wall Street Journal reported, citing sources.

JPMorgan (JPM.US) is said to be considering participating in this funding round through its Security and Resiliency Initiative.
~



AAStocks Financial News
Web Site: www.aastocks.com

香港2026年3月26日 /美通社/ -- 全球領先的指數公司MSCI（明晟）近日公佈最新年度環境、社會及管治（ESG）評級。本次2026年3月公佈的結果是根據MSCI 5.0版最新評級標準得出的，復星國際有限公司（香港聯交所股份代號：00656，簡稱「復星國際」或「復星」 或「集團」）憑藉在ESG各維度的優異表現，評級由AA躍升至AAA。這是復星國際自2021年首次獲評AA以來，歷經五年持續深耕，首次榮獲MSCI ESG最高評級，彰顯了復星在可持續發展領域的成就與全球領先地位。

MSCI ESG評級是全球投資機構廣泛採用的ESG評價體系，其評級結果已成為評估企業可持續發展績效與長期投資價值的重要參考。此次復星國際榮升AAA級，標誌著復星在環境、社會及管治方面的綜合管理水平達到全球同業領先水平，尤其在負責任投資、商業道德、清潔技術機遇等關鍵議題上持續保持行業領先優勢。

五年深耕，從AA到AAA的跨越

回顧復星在MSCI ESG評級中的進階之路，每一步都印證了復星在可持續發展領域的堅定投入與持續進步。2021年，復星國際MSCI ESG評級由A躍升至AA，成為當時大中華地區唯一一家獲評AA的綜合型企業。此後，集團連續維持AA評級，持續鞏固這一領先地位。

此次評級從AA晉升至AAA，不僅是MSCI對復星國際過去五年ESG工作的充分肯定，更標誌著集團在可持續發展領域完成了從「優秀」到「卓越」的跨越。這一成績的取得，得益於復星國際長期以來將ESG理念深度融入企業戰略與日常運營，建立了自上而下、貫穿全集團的ESG管治架構與管理體系。

構建長效機制，ESG與績效全面掛鈎

復星始終秉持「修身、齊家、立業、助天下」的企業初心，將可持續發展作為企業發展的核心驅動力。集團建立了自上而下的ESG提升長效機制，將ESG管理績效納入執行董事績效評估體系，並將考核範圍延伸至集團CEO及各業務集團負責人。

在管治架構上，復星國際在董事會下設立ESG董事委員會，由獨立非執行董事擔任主席，協助董事會指導及監察ESG工作的開展。在管理層面，集團設立ESG決策委員會，為ESG戰略落地提供決策支持；在執行層面，成立ESG管理委員會及ESG工作小組，確保ESG風險管理和內部監控系統的有效運行。

踐行綠色承諾，引領氣候行動

面對全球氣候變化挑戰，復星國際積極響應國家「雙碳」目標，於2021年向社會承諾：「力爭於2028年實現碳達峰、2050年實現碳中和」。集團成立碳中和委員會和工作組，積極推動碳中和管理在全集團範圍內的貫徹與落實，並連續三年發佈氣候信息披露報告，對標氣候相關財務信息披露工作組（TCFD）建議及《國際財務報告準則S2號—氣候相關披露》要求，增加氣候行動透明度。

創新驅動，以科技賦能社會

復星國際堅持創新驅動戰略，推動旗下業務結出創新碩果，廣泛惠及全球患者。復宏漢霖自主研發的全球首個獲批一線治療SCLC的抗PD-1單抗，H藥漢斯狀®（斯魯利單抗，歐洲商品名：Hetronifly®）在歐洲及多個新興市場獲批用於一線治療廣泛期小細胞肺癌（ES-SCLC），在印尼和泰國獲批治療鱗狀非小細胞肺癌（sqNSCLC），並在德國、意大利、西班牙等7個歐盟成員國完成醫保准入。截至2025年，H藥已在40餘個國家和地區獲批上市，並持續在肺癌和消化道腫瘤上取得突破，劍指多項「全球首個」。復星醫藥自主研發的注射用青蒿琥酯累計救治全球逾8,800萬重症瘧疾患者，累計供應超過4.4億支，持續為援非抗瘧貢獻「中國方案」。

助天下初心，積極回饋社會

為更好地履行企業社會責任，復星基金會於2012年成立，在全球應急馳援、鄉村振興、健康、教育、文化藝術及青少年發展等領域持續創造社會價值。鄉村醫生項目自2017年底啟動以來，已覆蓋全國16個省的78個重點幫扶縣，支持2.5萬名鄉村醫生，惠及中西部300萬戶基層家庭。該項目更於2024年入選聯合國全球契約組織發起的「二十年二十佳」企業可持續發展案例。

國際權威評級持續認可

除MSCI ESG評級外，復星國際在可持續發展領域的表現亦獲得多家國際權威機構的廣泛認可。截至目前，復星國際標普全球CSA評分達73分，持續保持全球同業領先水平，並入選標普全球《可持續發展年鑒2026》；恒生可持續發展評級保持AA-，連續六年入選恒生可持續發展企業基準指數成份股；富時羅素FTSE ESG評分保持4.2分領先水平，連續五次入選富時羅素社會責任指數（FTSE4Good Index Series）成份股，在環境供應鏈、反腐敗、風險管理、社會供應鏈與企業管治等多個維度獲得5.0滿分評價。

未來，復星國際將繼續深耕產業，深化創新及全球化佈局，以更高標準、更強行動力推動ESG工作，堅定踐行「讓全球家庭生活更幸福」的使命，為客戶創造長遠價值。

Connecting a Landmark Art Event Through Innovation and Technology, Redefining the Premium Membership Experience

HONG KONG, March 26, 2026 /PRNewswire/ -- China Mobile Hong Kong Company Limited ("China Mobile Hong Kong"), through its premium service brand GoTone Privilege Club, has partnered with Art Basel Hong Kong to proudly present the globally initiative for art of the digital era "Zero 10", marking its debut in Asia. Through this international arts and cultural occasion, GoTone Privilege Club further demonstrates its brand philosophy of connecting technology with art, culture and lifestyle. The collaboration marks a breakthrough cross-sector partnership, opening the door for members to a new realm of premium experiences with a broader international perspective and enriching their extraordinary lifestyles.

Connecting the World Through Tech Art, Reimagining the Realm of Prestige

On 25 March, the first preview day of Art Basel Hong Kong, GoTone Privilege Club and Art Basel Hong Kong hosted an exclusive branded cocktail reception within the exhibition, attracting a distinguished gathering of media representatives, arts and cultural leaders, and notable personalities from across the city. Guests came together to witness the innovative energy sparked by the convergence of art and technology, while the immersive cultural atmosphere brought to life the brand's renewed vision and practice of premium membership service.

Amid the vibrant ambience, Noah Horowitz, Chief Executive Officer of Art Basel, delivered the opening welcome remarks, followed by Mr. Lei Liqun, Director and Executive Vice President of China Mobile Hong Kong, who was invited to address the audience. In his speech, Mr. Lei shared his vision for fostering deeper integration between technology, culture and lifestyle, underscoring GoTone Privilege Club's commitment to continually pushing beyond traditional service boundaries and curating more diverse, forward-looking and tastefully refined premium experiences for its members.

Mr. Lei Liqun said, "China Mobile has always been committed to building meaningful connections, connecting people with people, people with things, and things with things, while also connecting technology with everyday life. Today, we are delighted to extend that spirit of connection into the realm of art through our partnership with Art Basel Hong Kong, opening up broader cultural horizons for our members. We firmly believe that truly exceptional service goes beyond functionality. It is not only about connection, but also about inspiration."

A Shared Vision, Opening a New Dialogue Between Art and Technology

As Art Basel's global digital art project, "Zero 10" makes its debut in Asia this year, curated by Eli Scheinman, Curator and Program Lead of Zero 10, and proudly presented by GoTone Privilege Club. The exhibition brings together 14 participating entities, featuring a diverse range of practices, including generative systems, algorithmic art and AI-driven creations, fully showcasing the boundless possibilities of artistic expression in the digital age.

For GoTone Privilege Club, "Zero 10" represents more than a world-class artistic collaboration. It is also a profound alignment grounded in a shared vision. While "Zero 10" spotlights innovative expressions of art in the digital era and explores the limitless integration of the fusion of technology and art, GoTone Privilege Club has likewise been exploring how cutting-edge digital intelligence can unlock richer and more diverse cultural lifestyle experiences for its members.

It is precisely this shared pursuit of innovation, taste and future-forward living that has brought GoTone Privilege Club and Art Basel Hong Kong together, creating a compelling example of collaboration between technology and art. This partnership marks a significant milestone in the relationship between GoTone Privilege Club and Art Basel Hong Kong, presenting a refreshing arts experience while inviting members to explore a broader and more layered world of culture and lifestyle.

Building on the Past, Expanding the Landscape of Member Privileges

Through an evolving portfolio of exclusive privileges and curated experiences, GoTone Privilege Club goes beyond telecommunications services to build a premium service platform that integrates culture, technology and lifestyle, empowering members to embrace elevated living and enjoy truly exceptional exclusivity.

This year, GoTone Privilege Club enters a new chapter with a refreshed brand identity. The brand will continue to enrich its privilege offerings and elevate service quality, delivering more refined and attentive experiences for its valued members. At the same time, it will further expand the services scope, opening the door together with members to world-class cultural and lifestyle experiences and ushering in a new chapter of bespoke premium living.

The VIP access experience to this international art event, presented by GoTone Privilege Club, is one of the brand's exclusive member privileges under its "access to rare and exceptional events". Looking ahead, GoTone Privilege Club will continue to be driven by innovation, deepen strategic partnerships with leading international platforms across culture, art and lifestyle, and further expand its privilege ecosystem. The brand aims to curate more distinctive, meaningful and memorable experiences for members, opening the door to an even richer and more rewarding world of prestige. More exciting experiences are yet to come.

About China Mobile Hong Kong Limited

China Mobile Hong Kong Company Limited ("China Mobile Hong Kong") is the wholly-owned subsidiary of China Mobile Limited (HKEx: 941), which is listed on the Fortune Global 500. CMHK was incepted in January 1997 and was the first mobile network operator to launch PCS services in Hong Kong.

As the world's leading mobile network brand with the largest customer base*, The Company offers innovative and comprehensive communications services, including voice, data, IDD and international roaming through 5G, 4G LTE and 3GHSPA and other technologies. The Company is committed to the development of 5G with new technologies such as artificial intelligence, internet of things, cloud computing and big data, integrating 5G applications in different industries, promoting the construction and development of smart city groups in Greater Bay Area.

* China Mobile (Hong Kong) Limited is a wholly-owned subsidiary of China Mobile Limited. As of 31 December 2024, China Mobile Limited had the largest number of mobile network subscribers in the world.

About Art Basel

Founded in 1970 by gallerists from Basel, Art Basel is today the premier fair for Modern and contemporary art, staging annual shows in Basel, Miami Beach, Hong Kong, Paris and Doha. Each show is distinguished by its host city and region, reflected in the participating galleries, the artworks on display, and the parallel programmes developed in collaboration with local cultural institutions. Through digital platforms such as Zero 10 and the Art Basel app, as well as initiatives including The Art Basel and UBS Global Art Market Report, The Art Basel and UBS Survey of Global Collecting, the Art Basel Awards, and the Art Basel Shop, Art Basel extends its influence well beyond the fair halls. For more information, please visit artbasel.com.

以創新科技連接藝術盛事 重塑尊尚會員體驗新定義

香港2026年3月26日 /美通社/ -- 中國移動香港有限公司（簡稱「中國移動香港」）旗下尊尚服務品牌「全球通優越會」（GoTone Privilege Club），攜手巴塞爾藝術展香港展會（Art Basel Hong Kong），隆重呈獻全球矚目的數碼藝術項目「Zero 10」，見證其亞洲首秀。透過是次國際藝文饗宴，「全球通優越會」進一步體現品牌以科技連結藝術、文化與生活方式的理念，標誌雙方達成突破性跨界合作，為會員開啟更具國際視野的尊尚體驗新境界，拓展非凡生活體驗。

科技藝術通全球 尊尚境界新詮釋

於3月25日，巴塞爾藝術展香港展會預展首日，由「全球通優越會」與Art Basel Hong Kong舉行了展覽內專屬品牌雞尾酒會，吸引眾多傳媒代表、藝文翹楚及城中名人親臨現場，共同見證藝術與科技交匯所綻放的創新魅力，並透過沉浸式藝文氛圍，演繹品牌對尊尚會員服務的全新想像與實踐。在熱烈的氛圍中，Art Basel首席執行官Noah Horowitz首先發表了歡迎辭，隨後特邀中國移動香港董事兼行政副總裁雷立群先生發表致辭，雷立群先生分享了對推動科技、文化與生活方式深度融合的願景，突顯「全球通優越會」持續突破傳統服務疆界，積極為會員打造更多元、更前瞻及更富品味的尊尚體驗。

雷立群先生表示：「一直以來，中國移動都致力做好『連接』，連接人與人、人與物、物與物，也連接科技與生活。今天，我們很高興把這份連接延伸到藝術，透過與巴塞爾藝術展香港展會合作，為會員開啟更廣闊的文化視野。我們深信，好的服務不止於功能，更在於體驗；不止於連接，更在於啟迪。」

理念契合共鳴 開啟藝術與科技新對話

作為巴塞爾藝術展的全球數碼藝術項目，「Zero 10」 今年首度登陸亞洲，由 Eli Scheinman 策展，並由「全球通優越會」隆重呈獻。展區匯聚 14 個參展單位，涵蓋生成系統、演算法藝術及人工智能創作等多元形式，充分展現數碼時代下藝術創作的無限可能。

對「全球通優越會」而言，「Zero 10」不僅是一次國際級藝文合作，更是一場理念相契的深度連結。「Zero 10」聚焦數碼時代藝術的創新表達，探索科技與藝術融合的無限可能；而「全球通優越會」亦一直思考，如何透過前沿數智科技，為會員開啟更多元的文化生活體驗。

正因這份對創新、品味與未來生活方式的共同追求，促成了「全球通優越會」與 Art Basel Hong Kong攜手同行，締造科技與藝術跨界的經典範例，是次合作是「全球通優越會」與 Art Basel Hong Kong合作關係上的重要里程碑，共同呈現耳目一新的藝文體驗，與會員一同探索更廣闊、更具層次的藝文生活領域。

繼往開來 拓展會員權益版圖

透過多元化尊享禮遇與體驗延伸，「全球通優越會」不僅提供通訊服務，更致力打造融合文化、科技與生活方式的尊尚服務平台，讓會員「啟境頂級生活、臻享非凡專屬」。

今年，「全球通優越會」尊尚品牌以嶄新面貌登場。品牌將持續豐富權益內容、提升服務品質，為尊貴會員帶來更卓越、更貼心的體驗，並不斷拓展服務疆界，與會員一同推開通往世界級文化與生活方式體驗的大門，開啟專屬的尊尚生活新篇章。

「全球通優越會」呈獻的是次國際藝術盛事VIP尊貴通行體驗，正是會員「稀缺活動參與權」之一。展望未來，「全球通優越會」將繼續以創新為驅動，深化與國際頂級文化、藝術及生活方式平台的戰略合作，持續豐富會員權益版圖，為會員帶來更多別具意義且獨一無二的精彩體驗。敬請拭目以待。

關於中國移動香港有限公司

中國移動香港有限公司（簡稱「中國移動香港」）隸屬中國移動有限公司（簡稱「中國移動」），《財富》雜誌「全球500強」企業，香港聯交所股份代號：941；於1997年1月正式提供服務，成為全港首個PCS流動網絡商。

作為全球最多客戶流動網絡品牌*，公司透過5G SA/NSA、4G LTE等技術為客戶提供創新及多元化的通訊服務，包括話音、數據、IDD及國際漫遊等，並一直致力發展5G與人工智慧、物聯網、雲端計算、大數據等新技術結合，幫助各行各業實現5G的應用，推動大灣區智慧城市群建設與發展。

*中國移動香港有限公司為中國移動有限公司全資附屬公司。截至2024年12月31日，中國移動有限公司在全球擁有最多流動網絡客戶。

關於巴塞爾藝術展

巴塞爾藝術展於1970年由巴塞爾的藝廊創辦人成立，現今為全球頂尖的現當代藝術展會，每年於巴塞爾、邁阿密海灘、香港、巴黎及多哈舉行。每個展會均因各自的城市與地域而別具特色，具體體現在參展藝廊、展出作品，以及與當地文化機構為每屆展會合作策劃的同期活動內容之中。通過諸如「Zero 10」項目與巴塞爾藝術展應用程式等數碼平台，以及《巴塞爾藝術展與瑞銀集團環球藝術市場報告》、《巴塞爾藝術展與瑞銀集團環球藝術收藏調查報告》、巴塞爾藝術獎（Art Basel Awards）及巴塞爾藝術展商店及等新的項目，巴塞爾藝術展將自身影響力拓展至藝術展會之外。獲取更多信息，請訪問artbasel.com。

SHANGHAI, March 26, 2026 /PRNewswire/ -- Biomethanol from Shanghai Electric's Taonan project has been successfully bunkered onto the container vessel CMA CGM OSMIUM at Shanghai's Yangshan Port this month. The operation marks the first large-scale adoption of Chinese biomethanol by a global shipping leader, underscoring Shanghai Electric's expanding of its presence in green hydrogen and next-generation fuel technologies.

Coordinated by Shanghai International Port Group from March 5 to 6, the bunkering operation was completed through a simultaneous loading and bunkering model that enables efficient coordination between cargo handling and fuel supply.

The recipient vessel, a next‑generation methanol‑dual‑fuel container ship owned by the CMA CGM Group, was fueled with biomethanol produced by Shanghai Electric, validating the company's fully integrated supply chain model spanning biomethanol production, land‑sea intermodal logistics, and port‑side bunkering.

Shanghai Electric's Taonan project is China's first large-scale commercial biomethanol facility. Located in western Jilin Province, it leverages the region's abundant wind, solar, and biomass resources. The initiative integrates proprietary technologies, including oxygen‑blown pressurized biomass gasification, flexible wind‑powered hydrogen production, and CO₂‑rich syngas‑to‑methanol synthesis, to create a fully integrated biomethanol production system.

Compared with conventional coal‑based methanol, biomethanol delivers a significant reduction in full‑life‑cycle carbon emissions, offering concrete progress toward maritime decarbonization goals. It provides the global shipping industry with a reliable green fuel option, supporting the transition to low‑ and zero‑carbon operations.

This integrated "green power–green hydrogen–green methanol" system addresses local renewable energy consumption and biomass utilization, while offering the shipping industry a stable, efficient, and sustainable low‑carbon fuel. Following systematic optimization, the Taonan facility now operates continuously, producing biomethanol that meets international marine fuel standards and holds International Sustainability and Carbon Certification (ISCC EU). The initial phase has an annual output of 50,000 tons, with plans for further expansion.

"The successful bunkering marks a breakthrough for Shanghai Electric in the fields of green hydrogen and next‑generation fuels. Moving forward, Shanghai Electric will continue to deepen its R&D and industrial application of biomethanol technology, strengthening collaboration with global shipping and port operators. With independently developed core technologies and full‑chain solutions, we are committed to contributing solid momentum to the global energy transition and pursuing carbon neutrality in the maritime industry," a Shanghai Electric representative said.

Google Research released TurboQuant, a training-free compression algorithm that can compress the KV cache of large language models (LLM) to 3 bits without affecting model accuracy, on Tuesday (24th), according to foreign media.

In benchmark tests on Nvidia (NVDA.US)'s H100 GPUs, compared to unquantized 32-bit keys, the 4-bit TurboQuant can increase the efficiency of computing attention logits by up to 8x, while reducing the KV cache memory by at least 6x.

Memory stocks Sandisk (SDNK.US) and Micron Technology (MU.US) cascaded 3.5% and 3.4% each overnight (25th).
~

AASTOCKS Financial News
Website: www.aastocks.com

• 2025年產品銷售收入和商業化權利收入同比增長髮90%，達到人民幣5.74億元
• 耐立克^®（奧雷巴替尼）銷售收入同比增長81%，達到人民幣4.35億元
• 利生妥^®（利沙托克拉）2025年上市後五個月實現銷售收入人民幣7058萬元
• 九項註冊III期臨床研究正在全球範圍內進行，其中四項已獲美國FDA和歐洲EMA許可
• 中文（普通話）投資者會議和網絡直播將於北京時間2026年3月26日上午10:00 / 美國東部時間2026年3月25日晚上22:00舉行；英文投資者網絡直播將於美國東部時間2026年3月26日上午8:00 / 北京時間晚上20:00舉行

美國馬里蘭州羅克維爾市和中國蘇州2026年3月26日  /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）（以下簡稱「亞盛醫藥」、「本公司」、「我們」或「我們的」）今日公佈了截至2025年12月31日的未經審計的財務業績，並介紹了臨床開發和商業化方面的重要進展。

亞盛醫藥董事長、CEO楊大俊博士表示：「2025年是亞盛醫藥全球化佈局提速的關鍵一年，我們在產品商業化、全球臨床開發、管線創新、資本市場等多維度均實現跨越式突破。

我們的商業化戰略正穩步推進，成果顯著，已成功構建以耐立克^®與利生妥^®為核心的『雙引擎』驅動格局，商業化表現持續向好。作為中國首個上市的國產原創Bcl-2抑制劑，利生妥^®於2025年7月成功獲批後快速填補臨床空白，上市以來銷售勢頭強勁。與此同時，2025年作為耐立克^®獲批適應症均被納入國家醫保藥品目錄後的首個完整銷售年份，其在中國的銷售額實現顯著增長，極大提升了患者的用藥可及性。

在臨床開發方面，亞盛醫藥多項全球註冊III期試驗正快速推進，其中4項已獲美國FDA和歐洲EMA許可。值得一提的是，公司新一代BTK降解劑APG-3288 IND已獲美國FDA、中國CDE許可，為全球創新管線佈局再添重要砝碼。

資本層面，公司2025年年初成功在納斯達克上市，成為首家先港股、後美股雙重主要上市的生物醫藥企業，並獲得募資淨額9.67億元人民幣。此外，公司在2025年7月完成一輪新股配售。這些舉措為公司全球創新研發與商業化拓展進一步注入了強勁財務動力。

2026年，我們將繼續聚焦患者未滿足需求，加速核心產品全球臨床開發，致力於成為血液腫瘤創新領域的全球領導者，為全球患者帶來更多獲益，並為股東創造更高價值。」

已上市產品和研發管線的主要進展

耐立克^®（通用名：奧雷巴替尼，研發代號：HQP1351）：中國首個獲批的第三代BCR-ABL抑制劑，已在中國獲批治療任何TKI耐藥、並伴有T315I突變的CML慢性期（-CP）和加速期（-AP）的成年患者；以及治療對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。

商業化進展

• 截至2025年12月31日止年度，耐立克^®在中國的銷售收入增長81%，從截至2024年12月31日止年度的人民幣2.41億元增至人民幣4.35億元。
• 自2025年1月起，耐立克^®的所有已獲批適應症均已被納入中國國家醫保藥品目錄（NRDL），這顯著提升了該藥物的可負擔性和可及性。
• 截至2025年12月31日，耐立克^®在全國准入的醫院和DTP藥房共達到825家，較截至2024年12月31日的734家增長12.4%。期間准入醫院數量由260家增至355家，同比增長約36.5%。

臨床進展

• 公司正持續為POLARIS-1研究招募患者。POLARIS-1為一項獲美國FDA和歐洲EMA許可的、評估耐立克^®聯合化療對比研究者選擇的TKI聯合化療治療新診斷費城染色體陽性（Ph+）急性淋巴細胞白血病（ALL）患者的全球註冊III期臨床研究。POLARIS-1研究的首批數據已在第67屆美國血液學會（ASH）年會上公佈，數據顯示誘導治療結束時患者的MRD陰性完全緩解（CR）率為64.2%，且至目前安全性良好。
• 公司正持續為POLARIS-2研究招募患者。POLARIS-2為一項獲美國FDA和歐洲EMA許可的、評估耐立克^®用於治療伴有或不伴有T315I突變的經治CML-CP成年患者的全球註冊III期臨床研究。
• 公司正在持續為POLARIS-3研究招募患者。POLARIS-3為一項評估耐立克^®用於治療既往系統性治療失敗的琥珀酸脫氫酶（SDH）缺陷型胃腸間質瘤（GIST）患者的註冊III期臨床研究。
• 公司正持續在早期臨床試驗中評估耐立克^®聯合Bcl-2抑制劑利生妥^®的療效。

預期進展

• 持續推進POLARIS-1、POLARIS-2和POLARIS-3研究的患者入組工作。

利生妥^®（通用名：利沙托克拉，研發代號：APG-2575）：新型口服Bcl-2選擇性抑制劑，通過選擇性抑制Bcl-2蛋白，恢復癌細胞的正常凋亡過程，從而達到治療腫瘤的目的。該品種在多種血液腫瘤和實體瘤治療領域具備廣闊的單藥和聯合治療潛力。

商業化進展

• 利生妥^®於2025年7月10日獲中國國家藥品監督管理局（NMPA）批准附條件上市，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成年慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。該藥物的首批處方於7月25日開出，正式啟動其在中國的商業銷售。這使利生妥^®成為中國首個獲批上市的國產原創Bcl-2抑制劑，也是全球第二個獲批的Bcl-2抑制劑。
• 利生妥^®在2025年8月至12月的五個月期間，實現銷售收入人民幣7058萬。

臨床進展

• 公司正持續為GLORA-4研究招募患者。GLORA-4為一項獲美國FDA和歐洲EMA許可的、評估利生妥^®聯合阿扎胞甘（AZA）一線治療新診斷中高危骨髓增生異常綜合征（MDS）患者的全球註冊III期臨床研究。
• 公司正持續為GLORA-3研究招募患者。GLORA-3為一項評估利生妥^®用於一線治療新診斷老年或不耐受化療的急性髓系白血病（AML）患者的全球註冊III期臨床研究。
• 公司正持續為GLORA-2研究招募患者。GLORA-2為一項評估利生妥^®聯合BTK抑制劑阿可替尼對比免疫化療治療初治CLL/SLL患者的註冊III期臨床研究，旨在驗證該聯合療法作為一線治療的臨床價值。
• 公司正持續為GLORA研究招募患者。GLORA為一項獲美國FDA和歐洲EMA許可的、評估利生妥^®聯合BTK抑制劑治療BTK抑制劑經治CLL/SLL患者的全球註冊III期臨床研究。
• 公司正在中國持續推進利生妥^®單藥或聯合其他療法治療AML/MDS患者（包括對維奈克拉耐藥的患者）的Ib/II期臨床研究的患者入組。
• 公司正在美國持續推進利生妥^®聯合其他療法治療多發性骨髓瘤（MM）患者的Ib/II期臨床研究的患者入組。

預期進展

• 計劃啟動臨床研究，以驗證利生妥^®在克服維奈克拉耐藥方面的潛力。
• 持續推進GLORA、GLORA-2、GLORA-3、GLORA-4研究的患者入組工作。
• 計劃於2026年積極推動將利生妥^®納入中國國家醫保藥品目錄（NRDL）。

BTK降解劑APG-3288：亞盛醫藥基於其具有自主知識產權的蛋白靶向降解嵌合體（PROTAC）技術平台研發的首個新型高效和高選擇性BTK 降解劑。

進展

• 於2026年第一季度獲得美國食品藥品監督管理局（FDA）和中國國家藥品監督管理局藥品審評中心（CDE）的臨床試驗申請（IND）許可。

預期進展

• 計劃啟動一項全球多中心、開放性的I期臨床研究，旨在評估APG-3288在復發/難治性血液系統惡性腫瘤患者中的安全性、耐受性、藥代動力學（PK）特徵及初步療效。

2025年全年未經審計財務業績

截至2025年12月31日止年度，公司總收入由截至2024年12月31日止年度的人民幣9.81億元減少至人民幣5.74億元，減少人民幣4.07億元或41.5%。收入下降的主要原因是我們在截至2024年12月31日止年度期間錄得人民幣6.78億元的知識產權收入。耐立克^®2025年在中國市場的銷售收入由截至2024年12月31日止年度的人民幣2.41億元增長81%至人民幣4.35億元。利生妥^®於2025年7月初獲中國NMPA批准後，自7月底正式開始商業化銷售，在2025年最後五個月實現銷售收入人民幣7058萬元。

公司銷售和分銷開支由截至2024年12月31日止年度的人民幣1.96億元增長人民幣1.58億元或80.4%至截至2025年12月31日止年度的人民幣3.54億元。該增長主要源於利生妥^®和耐立克^®的商業化活動增加。

公司研發開支由截至於2024年12月31日止年度的人民幣9.47億元增長人民幣1.90億元或20.1%至截至2025年12月31日止年度的人民幣11.37億元。該增長源於臨床試驗費用增加。

公司行政開支由截至2024年12月31日止年度的人民幣1.87億元增長人民幣0.59億元或31.6%至截至2025年12月31日止年度的人民幣2.46億元。該增長主要由於新增員工招聘所致。

公司融資成本由截至於2024年12月31日止年度的人民幣0.64億元減少人民幣0.10億元或16.1%至截至2025年12月31日止年度的人民幣0.54億元。這主要由於銀行借款利率下降所致。

截至2025年12月31日止年度，公司錄得其他開支人民幣0.74億元，而截至2024年12月31日止年度為人民幣0.09億元。增加的人民幣0.65億元主要是由於2025年與收購廣州順健生物醫藥科技有限公司相關的或有對價公允價值損失增加所致。

截至2025年12月31日止年度，公司虧損為人民幣12.43億元，而截至2024年12月31日止年度虧損為人民幣4.06億元。

截至2025年12月31日，現金和銀行存款餘額為人民幣24.70億元，而截至2024年12月31日為人民幣12.61億元，剔除匯率影響後增長人民幣12.09億元，或95.9%。這一增長主要得益於2025年1月美國首次公開發售帶來的人民幣9.7億元淨收益以及2025年7月後續發行帶來的人民幣13.7億元淨收益。

投資者電話會議和網絡直播

亞盛醫藥將召開投資者網絡直播會議，討論2025年全年業績。

亞盛醫藥中文（普通話）投資者會議和網絡直播將於北京時間2026年3月26日上午10:00/美國東部時間2026年3月25日晚上22:00舉行。如需參加中文投資者活動或電話會議，請提前在此處註冊。

英文投資者電話會議和網絡直播將於美國東部時間2026年3月26日上午8:00 / 北京時間晚上20:00舉行。如需參加英文網絡直播，請提前在此處註冊。亞盛醫藥網站的公司活動頁面也將提供英文電話會議和演示的網絡重播。

關於未經審計財務信息的聲明

本新聞稿包含截至2025年12月31日止財年的未經審計年度財務信息，該信息尚未經本公司審計師審計或審閱。截至 2025 年12月31日止財年的未經審計信息屬於初步信息，是基於目前可獲取的信息編製的，並且可能會因本公司財務報表審計工作的完成而發生變化。因此，在本公司截至2025年12月31日止財年的20-F表格年度報告中所包含的財務報表裡反映的本公司實際業績和財務狀況，可能會與本文中的財務信息存在調整或不同的列報方式，且這些差異可能是重大的。未經審計的合併財務報表涵蓋了本公司及其子公司的賬目。所呈現的所有期間的賬目均按照IFRS會計準則並依據美國證券交易委員會（「SEC」）的規則和條例進行了會計處理。

貨幣匯率信息

除非另有說明， 2025年和2024年的人民幣對美元的換算分別按照2025年12月31日和2024年12月31日紐約聯邦儲備銀行核證的紐約市中午買入匯率進行，即1美元兌換6.9931元人民幣和1美元兌換7.2993元人民幣。亞盛醫藥並未作出任何陳述，表示本新聞稿中提及的人民幣或美元金額無論如何都能夠或本可以按任何特定匯率兌換成美元或人民幣（視情況而定）。

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲MEA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2025年1月21日提交的經修訂的F-1表格註冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

SHANGHAI, March 26, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.8% to RMB 7.72 billion.

Innovation remained the engine of Hengrui's growth: Innovative drug sales increased by 26.1% year-on-year to RMB 16.34 billion, contributing 58.3% to total drug sales. This was driven by a robust pipeline across therapeutic areas, with oncology products contributing RMB 13.24 billion in revenue (+18.5% YoY), and non-oncology products contributing RMB 3.10 billion in revenue (+73.4% YoY).

Hengrui kept innovation at its core, with R&D expenditure reaching RMB 8.72 billion in 2025, accounting for 27.6% of total revenue, of which RMB 6.96 billion was expensed. During the year, the company secured seven approvals for Class 1 innovative drug, one for a Class 2 innovative drug, and six for new indications of marketed innovative drugs. The pace of regulatory progress accelerated with 15 NDA/BLAs accepted by the NMPA. Meanwhile, 28 drug candidates entered Phase III clinical trials, 61 progressed to Phase II, and 28 NMEs entered Phase I for the first time.

The company currently has over 100 proprietary innovative products in clinical development and is conducting more than 400 clinical trials. This robust portfolio will be further supported by approximately 53 innovative product and indication approvals anticipated during 2026-2028.

2025 marked another year of accelerated progress in Hengrui's global expansion. Licensing revenue rose 25.6% to RMB 3.39 billion, cementing the growing global recognition and value of the company's innovative portfolio. During the year, the company completed five overseas business development transactions for innovative drugs with leading MNCs and biotechs, highlighted by a strategic collaboration with GSK. In parallel, the company continued to advance its self-developed assets and global regulatory efforts, with multiple innovative assets entering global clinical trials.

Additionally, Hengrui successfully listed on the Hong Kong Stock Exchange, raising total proceeds of HK$11.4 billion (US$1.5 billion), including the over-allotment option — marking the largest pharmaceutical IPO in Hong Kong in the past five years and further strengthening its access to global capital.

Looking ahead, Hengrui will continue to focus on addressing unmet clinical needs with its differentiated innovative portfolio, placing equal emphasis on independent R&D and open collaboration to expand access to innovative drugs for patients worldwide.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the company's future growth prospects and pipeline potential. These statements are based on current expectations and assumptions and do not guarantee future performance. Actual results, developments, and business decisions may differ materially from these forward-looking statements. All information in this press release is as of the date of this press release, and Hengrui undertakes no duty to update such information unless required by law.